Price T Rowe Associates Inc I Teos Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 12,390 shares of ITOS stock, worth $106,058. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,390Holding current value
$106,058% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ITOS
# of Institutions
142Shares Held
36.6MCall Options Held
121KPut Options Held
738K-
Black Rock Inc. New York, NY3.73MShares$31.9 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.65MShares$31.2 Million0.45% of portfolio
-
Bvf Inc San Francisco, CA3.08MShares$26.3 Million0.81% of portfolio
-
Mpm Asset Management LLC Cambridge, MA2.74MShares$23.4 Million23.54% of portfolio
-
Tang Capital Management LLC San Diego, CA2.69MShares$23 Million1.04% of portfolio
About iTeos Therapeutics, Inc.
- Ticker ITOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,575,300
- Market Cap $305M
- Description
- Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...